Cargando…
Covid-19 and lung cancer: A greater fatality rate?
BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260554/ https://www.ncbi.nlm.nih.gov/pubmed/32505076 http://dx.doi.org/10.1016/j.lungcan.2020.05.034 |
_version_ | 1783540340735606784 |
---|---|
author | Rogado, Jacobo Pangua, Cristina Serrano-Montero, Gloria Obispo, Berta Marino, Almudena Martín Pérez-Pérez, Mar López-Alfonso, Ana Gullón, Pedro Lara, Miguel Ángel |
author_facet | Rogado, Jacobo Pangua, Cristina Serrano-Montero, Gloria Obispo, Berta Marino, Almudena Martín Pérez-Pérez, Mar López-Alfonso, Ana Gullón, Pedro Lara, Miguel Ángel |
author_sort | Rogado, Jacobo |
collection | PubMed |
description | BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission. |
format | Online Article Text |
id | pubmed-7260554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72605542020-06-01 Covid-19 and lung cancer: A greater fatality rate? Rogado, Jacobo Pangua, Cristina Serrano-Montero, Gloria Obispo, Berta Marino, Almudena Martín Pérez-Pérez, Mar López-Alfonso, Ana Gullón, Pedro Lara, Miguel Ángel Lung Cancer Article BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission. Elsevier B.V. 2020-08 2020-05-30 /pmc/articles/PMC7260554/ /pubmed/32505076 http://dx.doi.org/10.1016/j.lungcan.2020.05.034 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Rogado, Jacobo Pangua, Cristina Serrano-Montero, Gloria Obispo, Berta Marino, Almudena Martín Pérez-Pérez, Mar López-Alfonso, Ana Gullón, Pedro Lara, Miguel Ángel Covid-19 and lung cancer: A greater fatality rate? |
title | Covid-19 and lung cancer: A greater fatality rate? |
title_full | Covid-19 and lung cancer: A greater fatality rate? |
title_fullStr | Covid-19 and lung cancer: A greater fatality rate? |
title_full_unstemmed | Covid-19 and lung cancer: A greater fatality rate? |
title_short | Covid-19 and lung cancer: A greater fatality rate? |
title_sort | covid-19 and lung cancer: a greater fatality rate? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260554/ https://www.ncbi.nlm.nih.gov/pubmed/32505076 http://dx.doi.org/10.1016/j.lungcan.2020.05.034 |
work_keys_str_mv | AT rogadojacobo covid19andlungcanceragreaterfatalityrate AT panguacristina covid19andlungcanceragreaterfatalityrate AT serranomonterogloria covid19andlungcanceragreaterfatalityrate AT obispoberta covid19andlungcanceragreaterfatalityrate AT marinoalmudenamartin covid19andlungcanceragreaterfatalityrate AT perezperezmar covid19andlungcanceragreaterfatalityrate AT lopezalfonsoana covid19andlungcanceragreaterfatalityrate AT gullonpedro covid19andlungcanceragreaterfatalityrate AT laramiguelangel covid19andlungcanceragreaterfatalityrate |